Skip to content

Trial Summary

This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis

Acronym:

PXS5505-MF101

ACTRN/NCT /ethics:

NCT04676529

Scientific title:

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Sponsor / Cooperative group:

Pharmaxis

Trial & Patient Characteristics

Cancer TypeBlood
Trial TypeTreatment
PhasePhase I, Phase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-02-18
Anticipated End Date2022-06-22

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Stanley Cheung
Recruitment StatusNot Yet Recruiting